# Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years

> **NCT03325881** · PHASE3 · COMPLETED · sponsor: **Shire** · enrollment: 89 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder (ADHD)

## Interventions

- **DRUG:** SHP465
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03325881
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-09
- **Primary completion:** 2018-06-07
- **Final completion:** 2018-06-07
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2021-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03325881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03325881, "Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03325881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*